Flashcards on Retinal Vascular Diseases: Pathophysiology and Management
Retinal Vascular Diseases: Pathophysiology & Management Guide
Tap to flip · Swipe to navigate
Diabetic macular edema
37 cards
Card 1
Question: What is the general role of steroids in treating diabetic macular oedema (DME)?
Answer: Steroids are used as treatment for DME, often as second-line agents due to side effects (cataract progression, elevated IOP); they may be combined wit
Card 2
Question: Name two routes of triamcinolone delivery mentioned for DME.
Answer: Intravitreal and sub-Tenon (subtenon) injections of triamcinolone acetonide.
Card 3
Question: When might combining laser with intravitreal triamcinolone be beneficial?
Answer: For diffuse/extensive macular edema.
Card 4
Question: Why are steroids generally considered second-line agents for DME, especially in phakic patients?
Answer: Because of side effects including cataract progression and elevated intraocular pressure (IOP).
Card 5
Question: What is suprachoroidal triamcinolone and give the example product mentioned?
Answer: A formulation of triamcinolone for suprachoroidal delivery; example: SCS-TA (Xipere®, Bausch + Lomb) delivered via the SCS Microinjector® (Clearside).
Card 6
Question: Which intravitreal steroid implants are approved for DME according to the content?
Answer: Dexamethasone implant (Ozurdex, Allergan) and 0.19 mg fluocinolone implant (Iluvien, Alimera Sciences).
Card 7
Question: What is the recommended approach for non–center-involved macular edema?
Answer: Observation or photocoagulation.
Card 8
Question: What is the recommended treatment for center-involved macular edema?
Answer: Anti-VEGF therapy, with steroids as a possible adjunct (but steroids increase risk of elevated IOP).
Card 9
Question: List two main adverse effects of intravitreal steroids relevant to DME management.
Answer: Cataract progression and elevated intraocular pressure (IOP).
Card 10
Question: For what type of DME might an intravitreal steroid be favored despite risks?
Answer: Extensive or diffuse DME where combining with laser may be beneficial; or when anti-VEGF is unsuitable or ineffective (implied by second-line use).